Clinical and genetic characteristics in a Chinese cohort of complex spastic paraplegia type 4
Clinical Genetics · 2024
DOI: 10.1111/cge.14510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2024. Verfasst von Li Yao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Genetic Association Studies, Mutation, Phenotype, Spastic Paraplegia, Hereditary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Spastic paraplegia type 4 (SPG4), caused by SPAST mutations, is the most predominant subtype of hereditary spastic paraplegia. Most documented SPG4 patients present as pure form, with the complex form rarely reported. We described the clinical and genetic features of 20 patients with complex phenotypes of SPG4 and further explored the genotype–phenotype correlations. We collected detailed clinical data of all SPG4 patients and assessed their phenotypes. SPAST gene mutations were identified by Multiplex ligation‐dependent probe amplification in combination with whole exome sequencing. We further performed statistical analysis in genotype and phenotype among patients with various manifestations and different variants. Out of 90 SPG4 patients, 20 patients (male:female = 16:4) with additional neurologic deficits, namely complex form, were included in our study. The bimodal distribution of age of onset at 0–10 and 21–40 years old is concluded. On cranial MRI, obvious white matter lesions can be observed in five patients. We identified 9 novel and 8 reported SPAST mutations, of which 11 mutations were located in AAA (ATPase associated with various cellular activities) domain. The AAA cassette of spastin is the hottest mutated region among complex SPG4. All patients with cognitive impairment (CI) are males ( n = 9/9). Additionally, 80% patients with ataxia are due to frameshift mutations ( n = 4/5). Overall, our study summarized and analyzed the genetic and phenotypic characteristics of complex SPG4, making up over 1/5 of in‐house SPG4 cohort, among which CI and ataxia are the most common features. Further studies are expected to explore the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Neurology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
- Shanghai Neurological Rare Disease Biobank and Precision Diagnostic Technical Service Platform, Shanghai, China.
ORCID-Profile: Li Cao
Förderung
- Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Hospital Development Center
- Shanghai Municipal Health Commission
- China Postdoctoral Science Foundation Project
Zitieren
APA
Yao, L., Cao, Y., Zhang, C., Huang, X., Tian, W., & Cao, L. (2024). Clinical and genetic characteristics in a Chinese cohort of complex spastic paraplegia type 4. Clinical Genetics. https://doi.org/10.1111/cge.14510
Vancouver
Yao L, Cao Y, Zhang C, Huang X, Tian W, Cao L. Clinical and genetic characteristics in a Chinese cohort of complex spastic paraplegia type 4. Clinical Genetics. 2024. doi:10.1111/cge.14510
BibTeX
@article{Yao2024,
author = {Yao, Li and Cao, Yuwen and Zhang, Chao and Huang, Xiaojun and Tian, Wotu and Cao, Li},
title = {Clinical and genetic characteristics in a Chinese cohort of complex spastic paraplegia type 4},
journal = {Clinical Genetics},
year = {2024},
doi = {10.1111/cge.14510}
}
EUVIMED